This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gaipa G, Basso G, Maglia O, Leoni V, Cazzaniga G, Bugarin C et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19: 49–56.
Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99: 4386–4393.
van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.
Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MJW, Heyenbrok MW et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327–2336.
Diaz D, Prieto A, Barcenilla H, Monserrat J, Prieto P, Sánchez MA et al. Loss of lineage antigens is a common feature of apoptotic lymphocytes. J Leukoc Biol 2004; 76: 609–615.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van der Sluijs-Gelling, A., van der Velden, V., Roeffen, E. et al. Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 19, 1845–1847 (2005). https://doi.org/10.1038/sj.leu.2403911
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403911
This article is cited by
-
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia
Leukemia (2013)
-
Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
Leukemia (2010)
-
Why and how to quantify minimal residual disease in acute lymphoblastic leukemia?
Leukemia (2007)
-
Reply to van der Sluijs-Gelling et al
Leukemia (2005)
-
Reply to Gaipa et al
Leukemia (2005)